Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 599 publications.

Cotter SP, Schwartz L, Strong TV, Bender RH, Fehnel S. The Prader-Willi syndrome anxiousness and distress behaviors questionnaire: development and psychometric validation. Value Health. 2022 Oct 4. doi: 10.1016/j.jval.2022.08.004

Wang SV, Pottegard A, Crown W, Arlett P, Ashcroft DM, Benchimol EI, Berger ML, Crane G, Goettsch W, Hua W, Kabadi S, Kern DM, Kurz X, Langan S, Nonaka T, Orsini L, Perez-Gutthann S, Pinheiro S, Pratt N, Schneeweiss S, Toussi M, Williams RJ. HARmonized protocol template to enhance reproducibility of hypothesis evaluating real-world evidence studies on treatment effects: a good practices report of a joint ISPE/ISPOR Task Force. Value Health. 2022 Oct 1;25(10):1663-72.

Schlichting M, Hennig M, Rudell K, McLeod L, Bennett B, Shaw J, Doward L, Molsen-David E, Chassany O. Is IQWIG's 15% threshold universally applicable in assessing the clinical relevance of patient-reported outcomes changes? an ISPOR special interest group report. Value Health. 2022 Sep;25(9):1463-8. doi: 10.1016/j.jval.2022.07.010

Drummond MF, Augustovski F, Bhattacharyya D, Campbell J, Chaiyakanapruk N, Chen Y, Galindo-Suarez RM, Guerino J, Mejia A, Mujoomdar M, Ollendorf D, Ronquest N, Torbica A, Tsiao E, Watkins J, Yeung K, ISPOR HTA Council Working Group on HTA in Pluralistic Healthcare Systems collaborators. Challenges of health technology assessment in pluralistic healthcare systems: an ISPOR Council Report. Value Health. 2022 Aug;25(8):1257-67. doi: 10.1016/j.jval.2022.02.006

Whalley D, Belongie K, Frangiosa T, Krasa H, Mladsi DM, Twiss J, Wolowacz S. Understanding the patient experience of erythropoietic protoporphyria and x-linked protoporphyria: a qualitative study. Poster presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).

Poulos C, Ng X, Mansfield C, Rosenberg S, Peay H, Lee J, Irony T, Ho M. Logical soundness in a discrete choice experiment study of benefit risk preferences. Presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).

Rothwell B, Sheikh K, Knight C, Kamgar F, Jain R, Mamtani R, Kurt M, Poretta T, Broughton E, Teitsson S. Cost-utility of Nivolumab versus observation for the adjuvant treatment of Urothelial Carcinoma (UC) for patients who are at high-risk of recurrence: a United States (US) payer perspective. Poster presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun;.

Anderson S, Talbird SE, Nossov M, Beattie N, Diaz-Mitoma F. Cost-effectiveness of 3-antigen vs. single-antigen vaccine for prevention of hepatitis B in adults in the United States. Poster presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).

Oglesby A, Davis AE, Mellott CE, Fraysse J, Swygard H, Brogan A. Estimating the number of individuals needed to treat with different pre-exposure Prophylaxis options to avoid 1 new HIV-1 infection in the United States. Poster presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).

Herring W, Mladsi DM, Ronquest NA. AD valorem: Alzheimer's disease, atopic dermatitis, and challenges for value assessment in chronic conditions. Poster presented at the ISPOR 2022 Conference; May 17, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).

Ciepielewska M, Hagan M, Houghton K, Hitchens A, Ansquer V, Silver SM. Real-world treatment patterns and healthcare resource utilization among patients diagnosed with erythropoietic protoporphyria and x-linked protoporphyria: results from a US electronic medical records study. Poster presented at the ISPOR 2022 Conference; May 17, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).

Xu X, Datto C, Kwiatek J, Meyers J, Candrilli S, Mines D, Stirnadel-Farrant H. Comparison of healthcare resource utilization and costs in patients with and without Bullous Pemphigoid: a retrospective analysis of US health insurance claims data. Poster presented at the ISPOR 2022 Conference; May 18, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).

Hawe E, Castro CV, Johannesen J, Belisario JM, Mordin M, Sawant R, Petrillo Billet J. Driving outcomes in mild cognitive impairment/Alzheimer's disease - a review of association between driving simulator measures and clinical outcomes assessments. Poster presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).

Hawe E, Castro CV, Johannesen J, Belisario JM, Mordin M, Sawant R, Billet JP. Impact of Huntington's disease on driving: a review of driving simulator measures and association with clinical outcomes assessments. Poster presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).

Davis A, Brogan A, Mellott CE, Fraysse J, Oglesby A. Cost-effectiveness of every two month Cabotegravir long-acting (CAB-LA) compared with daily oral Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) for pre-exposure Prophylaxis (PrEP) to prevent HIV-1 infection in the United States. Presented at the ISPOR 2022 Conference; May 10, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).

Hartley L, Harold S, Hawe E. A systematic review of the efficacy, safety and immunogenicity of plague vaccines. Poster presented at the ISPOR 2022 Conference; May 16, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).

Yi Z, Graham J, Diaz-Decaro J, Myers E, Buck P. The public health impact of routine vaccination in 16-40-year-old females for the prevention of cytomegalovirus and congenital cytomegalovirus in the United States. Poster presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).

Perugini M, Johnson TJ, Beume TM, Dong OM, Guerino J, Hu H, Kerr K, Kindilien S, Nuijten M, Ofili TU, Taylor M, Wong A, Freijer K. Are we ready for a new approach to comparing coverage and reimbursement policies for medical nutrition in key markets: an ISPOR special interest group report. Value Health. 2022 May;25(5):677-84. doi: 10.1016/j.jval.2022.01.011

Vass CM, Boeri M, Karim S, Marshall D, Craig B, Ho KA, Mott D, Ngorsuraches S, Badawy SM, Mühlbacher A, Gonzalez JM, Heidenreich S. Accounting for preference heterogeneity in discrete-choice experiments: an ISPOR Special Interest Group Report. Value Health. 2022 May;25(5):685-94.

Dong OM, Poonnen PJ, Winski D, Reed S, Vashistha V, Bates J, Kelley MJ, Voora D. Cost-effectiveness of tumor genomic profiling to guide first-line targeted therapy selection in patients with metastatic lung adenocarcinoma. Value Health. 2022 Apr;25(4):582-94. doi: 10.1016/j.jval.2021.09.017

Gnanasakthy A, Norcross L, (DeMuro) Romano C, Carson RT. A review of patient-reported outcome labeling of FDA-approved new drugs (2016-2020): counts, categories, and comprehensibility. Value Health. 2022 Apr;25(4):647-55. doi: 10.1016/j.jval.2021.10.006

Mauskopf J, Blake L, Eiden A, Roberts C, Hu T, Nyaku M. Economic evaluation of vaccination programs: a guide for selecting modeling approaches. Value Health. 2022 Jan 10. doi: 10.1016/j.jval.2021.10.017

Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu RF, Staniszewska S, CHEERS 2022 ISPOR Good Research Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. 2022 Jan;25(1):3-9. doi: 10.1016/j.jval.2021.11.1351

Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu RF, Staniszewska S. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II Good Practices Task Force. Value Health. 2022 Jan;25(1):10-31. doi: 10.1016/j.jval.2021.10.008

Spentzouris G, Bilitou A, Manga N, McCrink L, Pearson I, Mitchell S, Moss E, Rothwell B. Systematic literature review of cost and data sources for economic evaluations in hypercholesterolaemia and mixed dyslipidaemia from a UK perspective. Poster presented at the Virtual ISPOR Europe 2021; November 30, 2021. [abstract] Value Health. 2021 Dec; 24(12):S2.

Lunan M, Hartley L, Pearson I, Doyle S. Targeted literature review of the burden of illness in late-stage Duchenne Muscular Dystrophy (DMD). Poster presented at the Virtual ISPOR Europe 2021; November 3, 2021. [abstract] Value Health. 2021 Dec; 24(12):S2.

Carrico J, Mellott C, Talbird S, Abreu A, Merckx B, Vanderhaute J, Benchabane D, Dauby N, Ethgen O, Lepage P, Luyten J, Raes M, Simoens S, Van Ranst M, Bencina G, Nyaku MK. Economic evaluation of the pediatric immunization program in Belgium. Poster presented at the Virtual ISPOR Europe 2021; November 30, 2021. [abstract] Value Health. 2021 Dec; 24(12):S2.

Anderson S, Talbird SE, Fishman J, Mody-Patel N, Sarda SP. Budget impact of pegcetacoplan, a complement c3 inhibitor, for the treatment of paroxysmal nocturnal hemoglobinuria in US adults. Poster presented at the Virtual ISPOR Europe 2021; November 30, 2021. [abstract] Value Health. 2021 Dec; 24(12):S2.

D'Souza V, Njue A, Heyes A. DRG-based reimbursement and payment modalities for innovative remote patient monitoring technologies. Poster presented at the Virtual ISPOR Europe 2021; December 1, 2021. [abstract] Value Health. 2021 Dec; 24(12):S2.

Johnson N, Paradis AD, Dave V, Macahilig C, Johnson C, Stephens JM, Atzinger C. Healthcare resource use and activities of daily living status among adult patients with spinal muscular atrophy: a natural history multicountry chart review study. Poster presented at the Virtual ISPOR Europe 2021; November 2021. [abstract] Value Health. 2021 Dec; 24(12):S2.

Martin SA, Meckley LM, Harris NI, Chen KS, Leffler DA. Symptom assessment in adolescents and adults with celiac disease. Poster presented at the Virtual ISPOR Europe 2021; December 1, 2021. [abstract] Value Health. 2021 Dec; 24(12):S2.

DeMuro C. Two years of COVID-19: what has been the global impact on HRQoL and clinical outcomes? Presented at the Virtual ISPOR Europe 2021; November 2021. [abstract] Value Health. 2021 Dec; 24(12):S2.

Jen MH, Sonksen M, Kiiskinen U, Wolowacz S, Vickers AD, Hawe E. Surrogate outcomes for overall survival in pretreated non-small cell lung cancer: expanding the prediction range. Poster presented at the Virtual ISPOR Europe 2021; December 2021. [abstract] Value Health. 2021 Dec; 24(12):S2.

Gnanasakthy A, Barrett A, Norcross L, D’Alessio D, Romano (DeMuro) C. Use of patient and investigator global impression scales: a review of Food and Drug Administration–approved labeling, 2009 to 2019. Value Health. 2021 Jul;24(7):1016-23. doi: 10.1016/j.jval.2021.01.005

Kamgar F, Hughes R, Lucherini S. Developing a predictive algorithm to identify the key factors impacting on the transmission and fatalities from COVID-19. Value Health. 2021 Jun 1;24(Suppl 1):S114. doi: 10.1016/j.jval.2021.04.1237

Mansfield C, Nalysnyk L, Joshi D, Coulter J, Pulikottil-Jacob R. Patient and parent preferences for symptom control in ASMD Type B and A/B using best-worst scaling methodology. Poster presented at the Virtual ISPOR 2021 Conference; May 2021. [abstract] Value Health. 2021 May; 24(5).

Hufstader (Gabriel) M, Vaidya V, White-Means S, Dishmon B, Sudharshan L, Sharma G. What influences dental care among children? Poster presented at the 2011 ISPOR 16th Annual International Meeting; May 2011. Baltimore, MD. [abstract] Value Health. 2021 Apr; 14(3):A54.

Ciarametaro M, Houghton K, Wamble D, Dubois R. The dollar or disease burden: caps on health care spending may save money, but at what “cost” to patients? Value Health. 2021 Mar;24(3):388-96. doi: 10.1016/j.jval.2020.10.024v

Mauskopf J, Masaquel C, Huang L. Evaluating vaccination programs that prevent diseases with potentially catastrophic health outcomes: how can we capture the value of risk reduction? Value Health. 2021 Jan 1;24(1):86-90.

Aronsson M, Dunton K, Hawe E, Wolowacz S, Quoraishi S, Durrington P, Ray KK, Bilitou A. Building a cost-effectiveness MODEL framework from a payer's perspective to assess NOVEL treatments in primary hypercholesterolaemia and MIXED dyslipidaemia: challenges in a world of LDL-C lowering. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec; 23(S2).

Dorgali MV, Longo A, Vass C, Shields G, Harrison R, Boeri M. Exploring Antimicrobial Resistance (AMR) from a societal perspective: preferences and welfare impacts in the United Kingdom. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec; 23(S2).

D'Souza VK, Alderson D. Early access and targeted supply considerations in emerging markets. Poster presented at the Virtual 2020 ISPOR Europe; November 16, 2020. [abstract] Value Health. 2020 Dec; 23(S2):S656. doi: 10.1016/j.jval.2020.08.1524

Turner AJ, Vass C. Matching techniques in stated preferences for health. Presented at the Virtual ISPOR Europe 2020 Conference; November 9, 2020. [abstract] Value Health. 2020 Dec; 23(Supplement 2):S758. doi: 10.1016/j.jval.2020.08.2086

Stevenson A, Gildea L. A Medtech roadmap: new routes to market access in the UK NHS. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec; 23(S2):S576.

Vass C, Rigby D, Payne K. Watching ME watching you: understanding the effect of experimental setting on stated preferences. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec; 23(S2).

Noon K, Costello J, Krieger T, Rothwell B, Pearson I. Utility weight considerations in NICE immune checkpoint inhibitor oncology appraisals. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec; 23(S2).

Carrico J, La EM, Talbird SE, Chen YT, Nyaku MK, Carias C, Marshall GS, Roberts CS. Economic impact of routine childhood immunization in the 2017 United States birth cohort. Presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec 1; 23(Supplement 2):S427. doi: 10.1016/j.jval.2020.08.039

Singh P, Contente M, Shillington A, Dave V, Kiff C, Cotte FE, Macahilig C. Treatment and outcomes in recurrent metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): a chart review study in France, Germany and the United Kingdom. Poster presented at the Virtual ISPOR 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec 1; 23(Supplement 2):S427. doi: 10.1016/j.jval.2020.08.172

Shah SN, Hepp Z, Martin S, Harris N, Morgans A. Qualitative analysis of pain in patients with locally advanced or metastatic urothelial cancer. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec; 23(S2).

Herring W, Gould I, Haines P, Thompson R, Pemberton-Ross P. Predicted delays in dementia onset for an innovative therapy acting on beta-amyloid in patients with mild cognitive impairment due to Alzheimer's disease. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 16, 2020. [abstract] Value Health. 2020 Dec; 23(S2).